NUTEX HEALTH INC (NUTX) Stock Fundamental Analysis
NASDAQ:NUTX - Nasdaq - US67079U3068 - Common Stock - Currency: USD
Overall NUTX gets a fundamental rating of 3 out of 10. We evaluated NUTX against 108 industry peers in the Health Care Providers & Services industry. NUTX may be in some trouble as it scores bad on both profitability and health. NUTX is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
NUTX had negative earnings in the past year.
NUTX had a positive operating cash flow in the past year.
NUTX had negative earnings in each of the past 5 years.
In multiple years NUTX reported negative operating cash flow during the last 5 years.
1.2 Ratios
NUTX's Return On Assets of -9.38% is on the low side compared to the rest of the industry. NUTX is outperformed by 70.09% of its industry peers.
NUTX has a worse Return On Equity (-68.06%) than 72.90% of its industry peers.
With a decent Return On Invested Capital value of 5.82%, NUTX is doing good in the industry, outperforming 67.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.38% | ||
| ROE | -68.06% | ||
| ROIC | 5.82% |
ROA(3y)-41.94%
ROA(5y)-711.14%
ROE(3y)-178.6%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 9.45%, NUTX belongs to the top of the industry, outperforming 84.11% of the companies in the same industry.
Looking at the Gross Margin, with a value of 23.24%, NUTX is in line with its industry, outperforming 46.73% of the companies in the same industry.
NUTX's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.45% | ||
| PM (TTM) | N/A | ||
| GM | 23.24% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-30.93%
GM growth 5Y-21.9%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so NUTX is destroying value.
NUTX has more shares outstanding than it did 1 year ago.
NUTX has more shares outstanding than it did 5 years ago.
NUTX has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.21, we must say that NUTX is in the distress zone and has some risk of bankruptcy.
NUTX has a worse Altman-Z score (0.21) than 73.83% of its industry peers.
NUTX has a debt to FCF ratio of 14.17. This is a negative value and a sign of low solvency as NUTX would need 14.17 years to pay back of all of its debts.
NUTX has a Debt to FCF ratio (14.17) which is comparable to the rest of the industry.
NUTX has a Debt/Equity ratio of 4.49. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 4.49, NUTX is not doing good in the industry: 82.24% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.49 | ||
| Debt/FCF | 14.17 | ||
| Altman-Z | 0.21 |
ROIC/WACC0.91
WACC6.43%
2.3 Liquidity
NUTX has a Current Ratio of 1.77. This is a normal value and indicates that NUTX is financially healthy and should not expect problems in meeting its short term obligations.
NUTX has a better Current ratio (1.77) than 61.68% of its industry peers.
A Quick Ratio of 1.74 indicates that NUTX should not have too much problems paying its short term obligations.
NUTX has a better Quick ratio (1.74) than 63.55% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.77 | ||
| Quick Ratio | 1.74 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 68.13% over the past year.
The Revenue has grown by 26.03% in the past year. This is a very strong growth!
The Revenue has been growing by 428.61% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)68.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.67%
Revenue 1Y (TTM)26.03%
Revenue growth 3Y438.49%
Revenue growth 5Y428.61%
Sales Q2Q%25.62%
3.2 Future
The Earnings Per Share is expected to grow by 35.29% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 15.58% on average over the next years. This is quite good.
EPS Next Y54.14%
EPS Next 2Y51.06%
EPS Next 3Y35.29%
EPS Next 5YN/A
Revenue Next Year21.68%
Revenue Next 2Y17.99%
Revenue Next 3Y15.58%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
NUTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 45.42 indicates a quite expensive valuation of NUTX.
NUTX's Price/Forward Earnings is on the same level as the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.68, NUTX is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 45.42 |
4.2 Price Multiples
NUTX's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. NUTX is cheaper than 65.42% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of NUTX indicates a somewhat cheap valuation: NUTX is cheaper than 79.44% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.48 | ||
| EV/EBITDA | 12.44 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NUTX's earnings are expected to grow with 35.29% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y51.06%
EPS Next 3Y35.29%
5. Dividend
5.1 Amount
NUTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:NUTX (2/21/2025, 8:00:01 PM)
57.6
-4.05 (-6.57%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners16.4%
Inst Owner Change1.46%
Ins Owners2.22%
Ins Owner Change0%
Market Cap313.34M
Analysts82.22
Price Target64.94 (12.74%)
Short Float %0.88%
Short Ratio0.72
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.12
Dividend Growth(5Y)N/A
DP-11.03%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-263.14%
Min EPS beat(2)-602.61%
Max EPS beat(2)76.34%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)7.43%
Min Revenue beat(2)5.5%
Max Revenue beat(2)9.37%
Revenue beat(4)3
Avg Revenue beat(4)3.15%
Min Revenue beat(4)-4.34%
Max Revenue beat(4)9.37%
Revenue beat(8)4
Avg Revenue beat(8)0.87%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)22.96%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-29.82%
EPS NY rev (1m)0%
EPS NY rev (3m)-300.66%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.44%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.25%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 45.42 | ||
| P/S | 1.07 | ||
| P/FCF | 15.48 | ||
| P/OCF | 14.69 | ||
| P/B | 5.18 | ||
| P/tB | 10.22 | ||
| EV/EBITDA | 12.44 |
EPS(TTM)-2.39
EYN/A
EPS(NY)1.27
Fwd EY2.2%
FCF(TTM)3.72
FCFY6.46%
OCF(TTM)3.92
OCFY6.81%
SpS53.68
BVpS11.11
TBVpS5.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.38% | ||
| ROE | -68.06% | ||
| ROCE | 7.44% | ||
| ROIC | 5.82% | ||
| ROICexc | 6.66% | ||
| ROICexgc | 7.32% | ||
| OM | 9.45% | ||
| PM (TTM) | N/A | ||
| GM | 23.24% | ||
| FCFM | 6.93% |
ROA(3y)-41.94%
ROA(5y)-711.14%
ROE(3y)-178.6%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-30.93%
GM growth 5Y-21.9%
F-Score5
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.49 | ||
| Debt/FCF | 14.17 | ||
| Debt/EBITDA | 5.9 | ||
| Cap/Depr | 5.9% | ||
| Cap/Sales | 0.37% | ||
| Interest Coverage | 8.51 | ||
| Cash Conversion | 46.4% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.77 | ||
| Quick Ratio | 1.74 | ||
| Altman-Z | 0.21 |
F-Score5
WACC6.43%
ROIC/WACC0.91
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.13%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.67%
EPS Next Y54.14%
EPS Next 2Y51.06%
EPS Next 3Y35.29%
EPS Next 5YN/A
Revenue 1Y (TTM)26.03%
Revenue growth 3Y438.49%
Revenue growth 5Y428.61%
Sales Q2Q%25.62%
Revenue Next Year21.68%
Revenue Next 2Y17.99%
Revenue Next 3Y15.58%
Revenue Next 5YN/A
EBIT growth 1Y347.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year854.81%
EBIT Next 3Y124.74%
EBIT Next 5YN/A
FCF growth 1Y-2.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.83%
OCF growth 3YN/A
OCF growth 5YN/A